iShares Biotechnology ETF
899 hedge funds and large institutions have $5.32B invested in iShares Biotechnology ETF in 2024 Q1 according to their latest regulatory filings, with 102 funds opening new positions, 245 increasing their positions, 312 reducing their positions, and 66 closing their positions.
55% more first-time investments, than exits
New positions opened: 102 | Existing positions closed: 66
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
3% more funds holding
Funds holding: 872 → 899 (+27)
2% more capital invested
Capital invested by funds: $5.2B → $5.32B (+$115M)
0.28% more ownership
Funds ownership: 69.26% → 69.54% (+0.28%)
21% less repeat investments, than reductions
Existing positions increased: 245 | Existing positions reduced: 312
79% less call options, than puts
Call options by funds: $222M | Put options by funds: $1.07B
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$141M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$92.2M |
| 3 |
GAA
Global Assets Advisory
Orlando,
Florida
|
+$65.7M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$57.3M |
| 5 |
Citigroup
New York
|
+$51.2M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$333M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$108M |
| 3 |
JP Morgan Chase
New York
|
-$57.2M |
| 4 |
IUHSA
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
|
-$29.2M |
| 5 |
MPM
MBB Public Markets
Chicago,
Illinois
|
-$18.8M |
IBB Hedge Fund Activity: Q1 2024 in Review
899 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2024, worth a combined $5.32B — up 2.2% from $5.2B a quarter earlier.
Buyers outnumbered sellers: 102 funds opened new IBB positions and 66 closed out — a net gain of 36 holders — while 245 added to existing stakes and 312 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $141M. The largest seller was Morgan Stanley, cutting an estimated $333M.
- 899 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2024, up from 872 in Q4 2023.
- Funds reported $5.32B of iShares Biotechnology ETF stock for Q1 2024, up 2.2% quarter-over-quarter.
- 102 funds opened new iShares Biotechnology ETF positions in Q1 2024 and 66 closed out, a net change of +36 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2024 was Goldman Sachs, an estimated $141M added.
- The largest iShares Biotechnology ETF seller in Q1 2024 was Morgan Stanley, an estimated $333M sold.
Based on aggregated 13F filings for Q1 2024.